Pacific Biosciences of California (PACB)
Pacific Biosciences of California Revenues: 10.04M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
PACB Revenues Rankings
| Overall | 13th percentile | 3838 of 4432 |
| Sector | 32nd percentile | 319 of 471 in Healthcare |
| Industry | 50th percentile | 66 of 132 in Biotechnology |
PACB Revenues Range, Past 5 Years
| Minimum | 0.22M | Sep 2010 |
| Maximum | 12.44M | Dec 2011 |
| Average | 5.064M |
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity.
Learn More
You may also be interested in these PACB related companies
PACB News
Unusual 11 Mid-Day Movers 05/25: (GNOM) (UPI) (RPRX) Higher; (TLB) (DCTH) (PAY) Lower
May 25, 1:42PM Street Insider
May 25, 1:42PM Street Insider
Elan Corporation plc, Quest Software Among Stocks Up on High Volume Friday
May 25, 12:33PM Fox Business
May 25, 12:33PM Fox Business
$PACB Mentioned more than normal on StockTwits - Currently at 7 x average daily social activity
about 6 days ago by TradeIdeasQuant
about 6 days ago by TradeIdeasQuant
$PACB nice , out of most, now my pick is $CYTR l/f watch this one
about 6 days ago by 3DTradingtrader
about 6 days ago by 3DTradingtrader
$PACB forms bearish "Top Triangle" chart pattern. http://stks.co/3t4A
about 14 days ago by RecogniaEvents
about 14 days ago by RecogniaEvents
$PACB http://stks.co/3q24 All isn’t lost for the bulls.Indicators are showing positive divergences.There is good support 2.38
about 16 days ago by ACInvestorBlog
about 16 days ago by ACInvestorBlog
Helicos BioSciences Corporation Settles its Patent Litigation Against Pacific Biosciences
May 14, 10:20AM Benzinga
May 14, 10:20AM Benzinga
$PACB forms bullish "Continuation Wedge" chart pattern. http://stks.co/3mUQ
about 21 days ago by RecogniaEvents
about 21 days ago by RecogniaEvents
$PACB http://stks.co/3lxA over 2.7, next stop 2.85 then the run to $3+ on chart. Short squeeze candidate 15.7 days to cover
about 21 days ago by ACInvestorBlog
about 21 days ago by ACInvestorBlog
$PACB http://stks.co/3lQE Increased volume up the right side of this base on the daily.CMF improving.Positive MACD divergence.
about 21 days ago by ACInvestorBlog
about 21 days ago by ACInvestorBlog
Pacific Biosciences of California, Inc. Announces First Quarter 2012 Financial Results
May 01, 4:00PM GlobeNewswire
May 01, 4:00PM GlobeNewswire
Pacific Biosciences of California, Inc. 1st Quarter 2012 Financial Results Call
Apr 18, 7:53PM GlobeNewswire
Apr 18, 7:53PM GlobeNewswire
PacBio® RS Compatible Products Now Available Through Pacific Biosciences Partner Program
Feb 15, 7:30AM Business Wire
Feb 15, 7:30AM Business Wire
Pacific Biosciences Releases Next Generation Chemistry and Software for PacBio® RS DNA Sequencing System
Feb 13, 7:30AM Business Wire
Feb 13, 7:30AM Business Wire
Pacific Biosciences of California, Inc. (PACB) Reports Q4 Loss of $0.42
Feb 07, 4:44PM Street Insider
Feb 07, 4:44PM Street Insider
Pacific Biosciences of California, Inc. 4th Quarter and Fiscal Year 2011 Financial Results Call
Jan 27, 6:35PM GlobeNewswire
Jan 27, 6:35PM GlobeNewswire
Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Pacific Biosciences of California, Inc.
Jan 06, 6:17PM Business Wire
Jan 06, 6:17PM Business Wire
Pacific Biosciences Names Michael W. Hunkapiller Chief Executive Officer
Jan 06, 12:15PM Business Wire
Jan 06, 12:15PM Business Wire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| PACB | 2.34 | +0.00 | +0.00% | 128.84M |
| OUTD | 6.55 | +0.10 | +1.55% | 166.47M |
| OTTR | 21.13 | +0.13 | +0.62% | 758.10M |
| OTT | 6.42 | +0.12 | +1.90% | 83.29M |
| OTEX | 48.36 | +0.17 | +0.35% | 2.793B |
| OSUR | 10.34 | +0.03 | +0.29% | 496.74M |
| OSTK | 6.66 | +0.12 | +1.83% | 153.17M |
| OSN | 0.9161 | -0.03 | -3.57% | 18.32M |
| OSIS | 63.77 | +0.07 | +0.11% | 1.259B |
| OSIR | 6.32 | -0.66 | -9.46% | 229.15M |
